Status:
TERMINATED
Effectiveness of Rosuvastatin at Preventing the Progression of Atherosclerosis in HIV Positive Patients
Lead Sponsor:
University of British Columbia
Collaborating Sponsors:
AstraZeneca
CIHR Canadian HIV Trials Network
Conditions:
Atherosclerosis
HIV Infections
Eligibility:
All Genders
35+ years
Phase:
PHASE4
Brief Summary
Rosuvastatin is a drug used to lower cholesterol, which also has other cardiovascular benefits. The goal of this project is to determine if rosuvastatin is effective at slowing the development of hear...
Detailed Description
HIV+ patients with at least one cardiovascular risk factor will be randomized to either rosuvastatin 10mg/day or placebo for a period of 96 weeks. B-mode carotid ultrasound will assess the primary out...
Eligibility Criteria
Inclusion
- HIV positive, at least one cardiovascular disease risk factor
Exclusion
- Diabetes
- Previous vascular disease
- Muscular disease
- Current use of other lipid lowering therapy
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2013
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT00673582
Start Date
April 1 2008
End Date
March 1 2013
Last Update
August 25 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The St. Paul's Hospital HIV Metabolic Clinic & The BC Centre for Excellence in HIV/AIDS
Vancouver, British Columbia, Canada, V6Z 1Y6